Published in Nat Genet on March 01, 2000
Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol (2002) 5.82
The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc Natl Acad Sci U S A (2002) 4.30
Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci U S A (2008) 3.84
In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol (2008) 3.79
AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood (2009) 3.65
Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol (2001) 3.38
Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev (2008) 3.30
Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J Virol (2005) 3.28
Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci U S A (2000) 2.83
Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors. J Virol (2002) 2.77
Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol (2002) 2.55
Assessing the potential for AAV vector genotoxicity in a murine model. Blood (2010) 2.48
Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer. J Virol (2001) 2.46
Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci U S A (2001) 2.20
Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. Nat Biotechnol (2005) 2.16
Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. Blood (2012) 2.10
Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver. J Virol (2005) 2.09
Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood (2013) 2.09
Genetic fate of recombinant adeno-associated virus vector genomes in muscle. J Virol (2003) 2.07
Adeno-associated virus type 2-mediated gene transfer: altered endocytic processing enhances transduction efficiency in murine fibroblasts. J Virol (2001) 2.03
Efficient gene targeting mediated by adeno-associated virus and DNA double-strand breaks. Mol Cell Biol (2003) 2.01
Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood (2008) 1.98
Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression. Virology (2008) 1.96
Human studies of angiogenic gene therapy. Circ Res (2009) 1.92
Treatment of human disease by adeno-associated viral gene transfer. Hum Genet (2006) 1.84
Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature (2013) 1.80
Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model. Blood (2004) 1.78
The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. J Clin Invest (2009) 1.73
Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX. Blood (2008) 1.72
A limited number of transducible hepatocytes restricts a wide-range linear vector dose response in recombinant adeno-associated virus-mediated liver transduction. J Virol (2002) 1.71
AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice. Blood (2015) 1.64
Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins. J Clin Invest (2002) 1.63
Adeno-associated virus type 2-mediated gene transfer: role of cellular FKBP52 protein in transgene expression. J Virol (2001) 1.58
Generation and characterization of chimeric recombinant AAV vectors. Mol Ther (2003) 1.54
Structure of adeno-associated virus serotype 5. J Virol (2004) 1.50
Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B. Blood (2010) 1.50
Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B. Mol Ther (2009) 1.49
Enhancement of muscle gene delivery with pseudotyped adeno-associated virus type 5 correlates with myoblast differentiation. J Virol (2001) 1.44
Heparin binding induces conformational changes in Adeno-associated virus serotype 2. J Struct Biol (2008) 1.44
Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency. ILAR J (2009) 1.43
Viral and nonviral delivery systems for gene delivery. Adv Biomed Res (2012) 1.42
Gene therapy for severe combined immunodeficiency: are we there yet? J Clin Invest (2007) 1.42
The relationship between terminal functionalization and molecular weight of a gene delivery polymer and transfection efficacy in mammary epithelial 2-D cultures and 3-D organotypic cultures. Biomaterials (2010) 1.37
Viral serotype and the transgene sequence influence overlapping adeno-associated viral (AAV) vector-mediated gene transfer in skeletal muscle. J Gene Med (2006) 1.36
Safety of AAV factor IX peripheral transvenular gene delivery to muscle in hemophilia B dogs. Mol Ther (2010) 1.35
Therapeutic application of RNAi: is mRNA targeting finally ready for prime time? J Clin Invest (2007) 1.34
A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. Mol Ther (2011) 1.29
Involvement of cellular double-stranded DNA break binding proteins in processing of the recombinant adeno-associated virus genome. J Virol (2001) 1.29
AAV's anatomy: roadmap for optimizing vectors for translational success. Curr Gene Ther (2010) 1.27
Biological treatment strategies for disc degeneration: potentials and shortcomings. Eur Spine J (2006) 1.25
Preclinical safety evaluation of AAV2-sFLT01- a gene therapy for age-related macular degeneration. Mol Ther (2010) 1.22
Lack of immunotoxicity after regional intravenous (RI) delivery of rAAV to nonhuman primate skeletal muscle. Mol Ther (2009) 1.21
Inverted terminal repeat sequences are important for intermolecular recombination and circularization of adeno-associated virus genomes. J Virol (2005) 1.21
Adeno-associated virus vectors: potential applications for cancer gene therapy. Cancer Gene Ther (2005) 1.19
Improved hepatic gene transfer by using an adeno-associated virus serotype 5 vector. J Virol (2002) 1.19
High-efficiency transduction of fibroblasts and mesenchymal stem cells by tyrosine-mutant AAV2 vectors for their potential use in cellular therapy. Hum Gene Ther (2010) 1.17
Efficient transduction of vascular endothelial cells with recombinant adeno-associated virus serotype 1 and 5 vectors. Hum Gene Ther (2005) 1.17
The state of the art of adeno-associated virus-based vectors in gene therapy. Virol J (2007) 1.16
Consequences of DNA-dependent protein kinase catalytic subunit deficiency on recombinant adeno-associated virus genome circularization and heterodimerization in muscle tissue. J Virol (2003) 1.16
Induction of robust immune responses against human immunodeficiency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells. J Virol (2006) 1.13
High-titer, wild-type free recombinant adeno-associated virus vector production using intron-containing helper plasmids. J Virol (2000) 1.12
Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors. J Virol (2001) 1.11
Recent developments in gene transfer: risk and ethics. BMJ (2005) 1.11
Tissue-specific transcriptional targeting of a replication-competent retroviral vector. J Virol (2002) 1.10
Gene therapy on the move. EMBO Mol Med (2013) 1.10
The gene therapy journey for hemophilia: are we there yet? Blood (2012) 1.10
Advances in Gene Delivery Systems. Pharmaceut Med (2011) 1.09
Structure of adeno-associated virus-2 in complex with neutralizing monoclonal antibody A20. Virology (2012) 1.09
Tolerance induction by viral in vivo gene transfer. Clin Med Res (2005) 1.07
Scalable generation of high-titer recombinant adeno-associated virus type 5 in insect cells. J Virol (2006) 1.07
Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis (2012) 1.07
Engineering biomaterial systems to enhance viral vector gene delivery. Mol Ther (2011) 1.07
Current gene therapy for stomach carcinoma. World J Gastroenterol (2001) 1.06
AAV9: over the fence and into the woods . . . Mol Ther (2011) 1.04
Safety and feasibility of high-pressure transvenous limb perfusion with 0.9% saline in human muscular dystrophy. Mol Ther (2011) 1.04
An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus. Proc Natl Acad Sci U S A (2001) 1.04
Anti-Abeta single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease. Neurobiol Dis (2006) 1.04
Animal models of hemophilia. Prog Mol Biol Transl Sci (2012) 1.04
Adeno-associated virus: a key to the human genome? Future Virol (2010) 1.03
Gene therapy for haemophilia. Br J Haematol (2008) 1.03
Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF molecule. Mol Ther (2010) 1.02
In vivo detection of gene expression in liver by 31P nuclear magnetic resonance spectroscopy employing creatine kinase as a marker gene. Proc Natl Acad Sci U S A (2001) 1.01
Chromosomal integration and homologous gene targeting by replication-incompetent vectors based on the autonomous parvovirus minute virus of mice. J Virol (2003) 0.99
Enhanced factor VIII heavy chain for gene therapy of hemophilia A. Mol Ther (2009) 0.99
Optimized adeno-associated virus (AAV)-protein phosphatase-5 helper viruses for efficient liver transduction by single-stranded AAV vectors: therapeutic expression of factor IX at reduced vector doses. Hum Gene Ther (2010) 0.98
Rescue of hereditary form of dilated cardiomyopathy by rAAV-mediated somatic gene therapy: amelioration of morphological findings, sarcolemmal permeability, cardiac performances, and the prognosis of TO-2 hamsters. Proc Natl Acad Sci U S A (2002) 0.97
A muscle-targeting peptide displayed on AAV2 improves muscle tropism on systemic delivery. Gene Ther (2009) 0.97
Minimizing the inhibitory effect of neutralizing antibody for efficient gene expression in the liver with adeno-associated virus 8 vectors. Mol Ther (2012) 0.96
Prevention and Reversal of Antibody Responses Against Factor IX in Gene Therapy for Hemophilia B. Front Microbiol (2011) 0.96
Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer. Proc Natl Acad Sci U S A (2002) 0.95
Translational data from adeno-associated virus-mediated gene therapy of hemophilia B in dogs. Hum Gene Ther Clin Dev (2015) 0.95
Heat-shock treatment-mediated increase in transduction by recombinant adeno-associated virus 2 vectors is independent of the cellular heat-shock protein 90. J Biol Chem (2004) 0.95
Retrograde gene delivery to hypoglossal motoneurons using adeno-associated virus serotype 9. Hum Gene Ther Methods (2012) 0.95
Gene therapy: progress and predictions. Proc Biol Sci (2015) 0.94
Gene therapy for hemophilia. Front Biosci (Landmark Ed) (2015) 0.94
The potential of adeno-associated viral vectors for gene delivery to muscle tissue. Expert Opin Drug Deliv (2014) 0.94
The major human rhinovirus receptor is ICAM-1. Cell (1989) 7.81
Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut (1999) 7.14
The length of the cervix and the risk of spontaneous premature delivery. National Institute of Child Health and Human Development Maternal Fetal Medicine Unit Network. N Engl J Med (1996) 5.52
Oligodeoxynucleotides containing synthetic abasic sites. Model substrates for DNA polymerases and apurinic/apyrimidinic endonucleases. J Biol Chem (1987) 4.97
Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med (1999) 4.61
Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med (2000) 3.94
Use of a protein-blotting procedure and a specific DNA probe to identify nuclear proteins that recognize the promoter region of the transferrin receptor gene. Proc Natl Acad Sci U S A (1985) 3.91
Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci U S A (1997) 3.84
Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet (1995) 3.74
Structure of a human rhinovirus complexed with its receptor molecule. Proc Natl Acad Sci U S A (1993) 3.62
Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet (1993) 3.58
Gene transfer, expression, and molecular cloning of the human transferrin receptor gene. Cell (1984) 3.42
The preterm prediction study: significance of vaginal infections. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol (1995) 3.38
The relation of preoperative coagulation findings to diagnosis, blood usage, and survival in adult liver transplantation. Transplantation (1985) 3.38
The human transferrin receptor gene: genomic organization, and the complete primary structure of the receptor deduced from a cDNA sequence. Cell (1984) 3.14
The preterm prediction study: maternal stress is associated with spontaneous preterm birth at less than thirty-five weeks' gestation. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol (1996) 3.09
Bleomycin-induced strand-scission of DNA. Mechanism of deoxyribose cleavage. J Biol Chem (1981) 3.00
Successful fetal surgery for spina bifida. Lancet (1998) 2.94
Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med (2000) 2.82
NMR structural studies of the ionizing radiation adduct 7-hydro-8-oxodeoxyguanosine (8-oxo-7H-dG) opposite deoxyadenosine in a DNA duplex. 8-Oxo-7H-dG(syn).dA(anti) alignment at lesion site. Biochemistry (1991) 2.59
Site-specific mutagenesis using a gapped duplex vector: a study of translesion synthesis past 8-oxodeoxyguanosine in E. coli. Mutat Res (1991) 2.54
High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency. Gene Ther (2009) 2.54
Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver. J Virol (1999) 2.37
Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nat Genet (1993) 2.31
Mechanisms of receptor-mediated rhinovirus neutralization defined by two soluble forms of ICAM-1. J Virol (1991) 2.30
Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J Infect Dis (1994) 2.26
Members of the olfactory receptor gene family are contained in large blocks of DNA duplicated polymorphically near the ends of human chromosomes. Hum Mol Genet (1998) 2.21
Improvement in hindbrain herniation demonstrated by serial fetal magnetic resonance imaging following fetal surgery for myelomeningocele. JAMA (1999) 2.19
Mutagenesis of the N-(deoxyguanosin-8-yl)-2-amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine DNA adduct in mammalian cells. Sequence context effects. J Biol Chem (1999) 2.17
Influence of the oxidatively damaged adduct 8-oxodeoxyguanosine on the conformation, energetics, and thermodynamic stability of a DNA duplex. Biochemistry (1995) 2.09
Is anaesthesia evidence-based? A survey of anaesthetic practice. Br J Anaesth (1999) 2.08
Progress and prospects: immune responses to viral vectors. Gene Ther (2009) 2.05
The use of thromboelastography for the peripartum management of a patient with platelet storage pool disorder. Int J Obstet Anesth (2010) 2.04
Substrate specificity of Fpg protein. Recognition and cleavage of oxidatively damaged DNA. J Biol Chem (1994) 2.03
Fetal lung lesions: management and outcome. Am J Obstet Gynecol (1998) 2.02
Liver transplantation in hemophilia A. Blood (1987) 1.98
Risk of developing AIDS in HIV-infected cohorts of hemophilic and homosexual men. JAMA (1989) 1.96
Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver. Blood (1998) 1.96
Mechanism of electrical enhancement of efficacy of antibiotics in killing biofilm bacteria. Antimicrob Agents Chemother (1994) 1.95
Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. Mol Ther (2001) 1.93
Induction of tolerance to factor VIII by transient co-administration with rapamycin. J Thromb Haemost (2011) 1.91
The preterm prediction study: the value of new vs standard risk factors in predicting early and all spontaneous preterm births. NICHD MFMU Network. Am J Public Health (1998) 1.90
Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain. J Virol (1995) 1.88
Human bone marrow CD34- cells engraft in vivo and undergo multilineage expression that includes giving rise to CD34+ cells. Exp Hematol (1998) 1.84
Segmental orthotopic hepatic transplantation as a means to improve patient survival and diminish waiting-list mortality. J Pediatr Surg (1991) 1.83
Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein. J Virol (1997) 1.79
The distribution of load across the knee. A comparison of static and dynamic measurements. J Bone Joint Surg Br (1980) 1.74
Is a CT guided needle better than a knife? Pediatr Pulmonol (1996) 1.71
Canine hemophilia B resulting from a point mutation with unusual consequences. Proc Natl Acad Sci U S A (1989) 1.68
Mutagenic potency of exocyclic DNA adducts: marked differences between Escherichia coli and simian kidney cells. Proc Natl Acad Sci U S A (1994) 1.67
Standardised trunk asymmetry scores. A study of back contour in healthy school children. J Bone Joint Surg Br (1983) 1.65
Assessing socioeconomic status in adolescents: the validity of a home affluence scale. J Epidemiol Community Health (2002) 1.65
Blood use in liver transplantation. Transfusion (1987) 1.63
Weight and dieting: examining levels of weight concern in British adults. Int J Obes Relat Metab Disord (2002) 1.63
Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males. Mol Ther (2001) 1.61
Major role of local immune responses in antibody formation to factor IX in AAV gene transfer. Gene Ther (2005) 1.58
Sequential urinalysis improves evaluation of fetal renal function in obstructive uropathy. Am J Obstet Gynecol (1995) 1.56
Circuits, hormones, and learning: vocal behavior in songbirds. J Neurobiol (1997) 1.55
Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. Mol Ther (2000) 1.55
Successful expression of human factor IX following repeat administration of adenoviral vector in mice. Proc Natl Acad Sci U S A (1996) 1.55
Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9. Mol Ther (2001) 1.54
Organ transplantation in HIV-positive patients with hemophilia. N Engl J Med (1990) 1.52
The preterm prediction study: a clinical risk assessment system. Am J Obstet Gynecol (1996) 1.51
NMR characterization of a DNA duplex containing the major acrolein-derived deoxyguanosine adduct gamma -OH-1,-N2-propano-2'-deoxyguanosine. J Biol Chem (2000) 1.51
A mutation in the propeptide of Factor IX leads to warfarin sensitivity by a novel mechanism. J Clin Invest (1996) 1.49
Haemophilia B: database of point mutations and short additions and deletions--fourth edition, 1993. Nucleic Acids Res (1993) 1.49
Development and implementation of computerized clinical guidelines: barriers and solutions. Methods Inf Med (2002) 1.48
Recombinant human erythropoietin reduces the need for erythrocyte and platelet transfusions in pediatric patients with sarcoma: a randomized, double-blind, placebo-controlled trial. J Pediatr (1996) 1.44
Thermodynamic consequences of an abasic lesion in duplex DNA are strongly dependent on base sequence. Biochemistry (1998) 1.44
Transcriptional regulation by iron of the gene for the transferrin receptor. Mol Cell Biol (1986) 1.42
Human factor IX corrects the bleeding diathesis of mice with hemophilia B. Blood (1998) 1.40
Successful use of extracorporeal membrane oxygenation (ECMO) during BMT for SCID. Bone Marrow Transplant (1998) 1.40
Acute toxic delirium in a patient using transdermal fentanyl. Anesth Analg (1992) 1.39
Superior in vivo response of recombinant factor VIII concentrate in children with hemophilia A. J Pediatr (1997) 1.39
Haemophilia B: database of point mutations and short additions and deletions--third edition, 1992. Nucleic Acids Res (1992) 1.36
8-oxodGTP incorporation by DNA polymerase beta is modified by active-site residue Asn279. Biochemistry (2000) 1.35
Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost (1998) 1.35
AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects. Gene Ther (2008) 1.34
Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost (2001) 1.34
Liver transplantation in a hemophiliac. N Engl J Med (1985) 1.32
Optimized production of high-titer recombinant adeno-associated virus in roller bottles. Biotechniques (2003) 1.31
Long-term repopulating ability of xenogeneic transplanted human fetal liver hematopoietic stem cells in sheep. J Clin Invest (1994) 1.29
Responses to the major acrolein-derived deoxyguanosine adduct in Escherichia coli. J Biol Chem (2000) 1.29
Haemophilia B: database of point mutations and short additions and deletions--second edition. Nucleic Acids Res (1991) 1.29
Engraftment and long-term expression of human fetal hemopoietic stem cells in sheep following transplantation in utero. J Clin Invest (1992) 1.28
The molecular cloning of a dispersed set of developmentally regulated genes which encode the major larval serum protein of D. melanogaster. Cell (1981) 1.27
Prophylactic immune tolerance induced by changing the ratio of antigen-specific effector to regulatory T cells. J Thromb Haemost (2009) 1.26
A new method for straightening DNA molecules for optical restriction mapping. Nucleic Acids Res (1997) 1.26
Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant (2006) 1.26
Translesional synthesis on DNA templates containing 8-oxo-7,8-dihydrodeoxyadenosine. Biochemistry (1993) 1.26